Introduction
Very early-onset inflammatory bowel disease (VEOIBD), caused by defects in interleukin-10 (IL-10) signaling, including defects in IL10, IL10RA, and IL10RB, is an autosomal recessive disorder [
1,
2]. This type of VEOIBD often presents as diarrhea, perianal diseases, oral ulcers, intestinal ulcers, perforation, and obstruction [
3,
4]. VEOIBD patients are refractory to conventional therapies and require early surgical intervention and further hematopoietic stem cell transplantation (HSCT) [
5,
6].
In our previously reported study, the complications of enterostomy and related risk factor analysis of VEOIBD with IL-10 signaling deficiency in our IBD center were determined [
7]. However, the long-term outcomes of these patients after enterostomy are still unclear, and some risk factors for stoma closure are especially unclear. This study aims to collect the data of these patients after enterostomy, report their long-term outcomes and shed light on higher quality management for VEOIBD patients with IL-10 signaling deficiency after enterostomy.
Methods
This study was approved by the Ethics Committee of the Children’s Hospital of Fudan University. The medical records of all children undergoing enterostomy for VEOIBD with IL-10 signaling deficiency from 2012.1 to 2022.7 in the Children’s Hospital of Fudan University were retrospectively assessed. Data on disease history, genetics, enterostomy, HSCT and stoma closure were reviewed retrospectively; the research methods and most of the patients were reported in our previous study [
8], however more details are described in this study. For the included patients, the available height, weight, weight-for-age (WFA) Z score, height-for-age (HFA) Z score, and BMI Z score were determined using the World Health Organization (WHO) Anthro software (version 3.2.2) [
4].
The decision to perform stoma closure primarily involved three factors. First, the intestinal lesions were much improved after colonoscopy examination. Second, immune reconstitution was successful after HSCT. Last, the severe enterostenosis or and perianal lesions were staged treated surgically before stoma closure.
Data were analyzed using SPSS 24.0 for Windows (SPSS Inc., Chicago, IL). Continuous data are presented as the mean and SD or median and interquartile range. Risk factors were analyzed with logistic regression. Because the traditional p level of 0.05 might fail to identify variables known to be important, we chose only factors that had P values < 0.1 in univariate analysis for inclusion and in multivariate analysis.
Discussion
VEO-IBD represents approximately 25% of cases of IBD-like colitis occurring during childhood and has greater potential for escalated treatment, such as extensive surgery and more intensive medical therapies [
9,
10]. The cumulative risk of bowel surgery in children with VEOIBD is approximately 14–15% by 5 years. For severe VEOIBD patients with IL10R gene mutations, enterostomy is always inevitable [
11,
12]. Our previous single-center retrospective study reported the complications of enterostomy and related risk factors in 22 VEOIBD patients with IL10R gene signaling deficiency [
7]. In this study, we collected 46 IL10R gene-mutated patients with enterostomy and followed up on their outcomes after HSCT, especially influencing factors for stoma closure.
The annual number of patients with enterostomy in our pediatric IBD center increased, as shown in Fig.
1B. There is a tendency for the number to increase because of the attention increasingly given to IL10R gene-mutated monogenic IBD patients. The timely management of VEO-IBD with perianal or severe intestinal lesions is important owing to the possible adverse effects on growth, development, and quality of life [
8]. For these patients, a combination of medical and surgical treatment was often required to control diseases [
10,
13]. Surgical treatment included emergency enterostomy and selective enterostomy depending on the condition of the disease [
14].
In our study, the emergency enterostomy group had a higher number of deaths than in the selective enterostomy group. The reason was that the patients in the emergency enterostomy group had severe illness and complications. Therefore, the patients in our center received medical and surgical intervention, when necessary, regardless of whether they were referred for transplantation [
8].
In this study, for IL10R-mutated VEOIBD patients, we found that timely surgery and enterostomy showed benefits for VEOIBD with IL-10 signaling deficiency. The timing of intervention, potential postoperative complications, economic burden and other related problems should be considered when an enterostomy is needed [
15]. Surgical intervention should be performed earlier because the perforations in monogenic IBD are usually insidious [
16]. Preventative enterostomies are suggested in preparation for HSCT among patients with severe anorectal complications. Clara et al. reported that the absence of perianal/rectal CD activity (HR 3.00; 95% CI 1.86–4.86;
p < 0.001) emerged as an independent predictor of a shorter time to stoma reversal [
17]. However, enterostomy only showed temporary benefits, and increasing time was associated with an increase in complication rates and increased length of hospital stay with loop ileostomy [
18]. In our study, only patients with HSCT had the chance for stoma closure. For those patients without HSCT, the enterostomy was still maintained, although they wished for stoma closure.
Åsa et al. reported that stomas were more common in elderly-onset patients than in pediatric-onset patients, with a 5-year cumulative incidence of 3.6% vs. 1.3% [
19]. In those patients, ileostomies were most common (64%), and 24.5% of the patients who underwent stoma surgery had perianal disease at the end of follow-up. Within 5 years of diagnosis, 0.8% of the incident patients had a permanent stoma. In our study, we found that 34.6% of the IL10R gene-mutated VEOIBD patients had an enterostomy, and eneterostomies were mainly performed in patients with perianal disease or severe intestinal lesions.
However, stoma closure is needed for the patients with perianal disease or severe intestinal disease to help them improve their quality of life and have good functional outcomes. Tracanelli et al. reported that anti-TNF-α was significantly related to successful closure techniques for patients with a rectovaginal fistula secondary to Crohn’s disease (
p = 0.007) [
20]. Because of the limited number of patients with rare diseases, there was no statistical difference in multiple intestinal lesions at the time of stoma closure. Delayed ileostomy closure was also associated with a nearly 7-fold increase in the risk of
Clostridium difficile infection (OR = 6.95, CI: 1.06–81.6;
P = 0.03) [
21]. In our study, we did not find any
Clostridium difficile infections in the delayed stoma closure group. For the VEOIBD patients with mutations in the IL10R gene, we and other groups showed that HSCT was the only possible cure for patients with IL-10 signaling deficiency, although it is associated with complications, including graft failure, GVHD and infections. After HSCT, all patients underwent stoma closure if the timing was appropriate, and the patients had no chance for stoma closure without HSCT. After follow-up, 41.3% (19/46) of our patients had permanent stoma closure.
Vogel, et al. reported a major morbidity rate of 23% (n = 66/292) following stoma closure in young children, most commonly comprising anastomotic leakage/stenosis, incisional hernia and adhesive obstructions [
19]. In our study, no patients died after stoma closure, and only anastomotic inflammation and ulcers were found in one patient. Growth and development delay compared with that of peers occurred, even though the patient was much improved.
Our study had limitations. First, VEOIBD with an IL10R gene mutation is still a rare disease, so the number of patients with enterostomy and HSCT was not sufficient, which may lead to statistical bias. For example, the factors of intestinal/perianal lesions and complications of HSCT were not significantly different in the patients with early and late stoma closure group. Future multicenter studies of patients with VEOIBD may be able to distinguish predictors for stoma closure. Furthermore, data on long-term stoma closure are lacking, and more long-term follow-up is needed.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.